• Explore /
  • Poster
  • / IMbrave150: Exploratory analysis to examine the association between bevacizumab (bev) ever being skipped and bev never being skipped in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bev in a global phase 3 study.

IMbrave150: Exploratory analysis to examine the association between bevacizumab (bev) ever being skipped and bev never being skipped in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bev in a global phase 3 study.

Abstract Video & Slides Poster

Authors

null

Masatoshi Kudo

Kindai University, Osaka, Japan;

Masatoshi Kudo , Kaoru Tsuchiya , Yu Yun Shao , Richard S. Finn , Peter R. Galle , Michel Ducreux , Ann-Lii Cheng , Tatsuya Yamashita , Hironori Koga , Kenichi Aoki , Kyoko Yamada , Takashi Asakawa , Yuki Nakagawa , Masafumi Ikeda

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03434379

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 538)

DOI

10.1200/JCO.2023.41.4_suppl.538

Abstract #

538

Poster Bd #

C8

Abstract Disclosures

Similar Posters

First Author: Michel Ducreux

First Author: Richard S. Finn

First Author: Kazuomi Ueshima

First Author: Han Chong Toh